Mifepristone

In-country availability of medical abortion medicines: a description of the framework and methodology of the WHO landscape assessments

Ulrika Rehnström Loi
Ndola Prata
Amy Grossman
Natalie Williams
Bela Ganatra
Antonella Lavelanet
2023

Background: Availability of quality-assured medical abortion medicines plays a crucial role in providing comprehensive abortion care. However, access to these medicines is still restricted for many abortion seekers. Increasing availability of affordable, quality-assured mifepristone and misoprostol is important to improve access to safe medical abortion services. Driven by the outcomes of a global consultation hosted by the World Health Organization and the Swedish International Development Cooperation Agency in 2018, we decided to holistically examine access to medical...

Landscape assessment of the availability of medical abortion medicines in India.

Priya Karna
Aparna Sharma
Amy Grossman
Madhur Gupta
Tapas Chatterjee
Natalie Williams
Ndola Prata
Annik Sorhaindo
Laurence Läser
Ulrika RehBela Ganatra
Pushpa Chaudhary
Bela Ganatra
2024

Background: Medical abortion with mifepristone and misoprostol can be provided up to 63 days' gestation in India. This accounts for 67.5 percent of all abortions in the country. We conducted an assessment to determine the availability of medical abortion medicines, specifically the combi-pack, in India.

Methods: We applied the World Health Organization landscape assessment protocol at the national level. The assessment protocol included a five-step adaptation of an existing availability framework, including online data collection, desk review,...

A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries

Amy Grossman
Ndola Prata
Sarah Jones
Laurence Läser
Bela Ganatra
Antonella Lavelanet
Natalie Williams
Chilanga Asmani
Hayfa Elamin
Leopold Ouedraogo
Lucy Sejo Maribe
Dina Vladimirovna Gbenou
Yelmali Clotaire Hien
Moussa Dadjoari
Fousséni Dao
Mariette Claudia Adame Gbanzi
Robert Mulunda Kanke
Franck Biayi Kanumpepa
Dudu Dlamini
Grace Motsoanku Mefane
Sirak Hailu Bantiewalu
Mary Nana Ama Brantuo
Olive Sentumbwe-Mugisa
Richard Mugahi
Olumuyiwa Adesanya Ojo
Adeniyi Kolade Aderoba
Ulrika Rehnström Loi
2024

Background: The use of medical abortion using either a combination of mifepristone and misoprostol, or misoprostol alone has contributed to increased safety and decreased mortality and morbidity. The availability of quality medical abortion medicines is an essential component in the provision of quality abortion care. Understanding the factors that influence the availability of medical abortion medicines is important to help in-country policymakers, program planners, and providers improve availability and use of medical abortion.

Methods: Using a...